Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
PARAPLATIN vs CLOFARABINE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Carboplatin, a platinum-based alkylating agent, forms interstrand and intrastrand DNA cross-links by binding to DNA guanine bases, inhibiting DNA replication and transcription, leading to cell cycle arrest and apoptosis.
Clofarabine is a purine nucleoside antimetabolite that inhibits DNA synthesis by reducing intracellular deoxynucleotide triphosphate pools via inhibition of ribonucleotide reductase, and by terminating DNA chain elongation through incorporation into DNA, leading to apoptosis.
Ovarian carcinoma: treatment of advanced ovarian carcinoma in combination with other chemotherapy agents,Non-small cell lung cancer: treatment of advanced NSCLC in combination with other agents,Off-label: head and neck cancer, bladder cancer, endometrial cancer, testicular cancer, small cell lung cancer
Treatment of relapsed or refractory acute lymphoblastic leukemia (ALL) in pediatric patients aged 1 to 21 years,Off-label: Treatment of acute myeloid leukemia (AML), myelodysplastic syndromes (MDS)
360 mg/m2 IV every 3 weeks or area under the curve (AUC) 4-6 mg/m L/min IV every 3-4 weeks using Calvert formula.
52 mg/m^2 intravenously over 2 hours daily for 5 consecutive days, repeated every 28 days.
Terminal elimination half-life: 2.6-5.1 hours (initial phase), 22-52 hours (terminal phase) for total platinum; 1.3-2.1 hours for ultrafilterable platinum. Clinically, the terminal half-life reflects slow release of protein-bound platinum.
Terminal elimination half-life: 5.2 hours (range 4-6 hours) in adult patients; clinically, this supports a 5-day continuous infusion schedule
Carboplatin is minimally metabolized in the liver; the majority of the drug is eliminated unchanged by renal excretion via glomerular filtration and tubular secretion. It is not extensively metabolized by cytochrome P450 enzymes.
Hepatic; primarily metabolized by deamination via cytidine deaminase to 6-ketoclofarabine, a major metabolite. Also undergoes phosphorylation intracellularly. CYP450 involvement is minimal.
Renal excretion: ~70-90% of platinum is excreted in urine within 24 hours, primarily as unchanged drug. Fecal excretion: <6%. Biliary excretion: minimal.
Renal: 49-60% as unchanged drug; biliary/fecal: minimal (<1%)
Protein binding: ~90% of circulating platinum is irreversibly bound to plasma proteins (primarily albumin) within 4 hours of infusion; only free drug is pharmacologically active.
47% bound to plasma proteins (primarily albumin)
Volume of distribution: 10-16 L/kg (total platinum), 0.3-0.5 L/kg (ultrafilterable platinum). High Vd indicates extensive tissue distribution, including into tumors.
Vd: 14.6 L/kg (range 10-20 L/kg); indicates extensive extravascular distribution and tissue binding
IV administration only; oral bioavailability is negligible (<2%) due to poor absorption and rapid degradation in GI tract.
IV: 100% (only IV route); oral: not approved
Creatinine clearance (Cr Cl) 41-59 m L/min: 250 mg/m2 IV every 3-4 weeks; Cr Cl 16-40 m L/min: 200 mg/m2 IV every 3-4 weeks; Cr Cl <15 m L/min: not recommended. Alternatively, AUC dosing: Cr Cl 41-59 m L/min: AUC 4; Cr Cl 16-40 m L/min: AUC 3; Cr Cl <15 m L/min: not recommended.
Clcr ≥ 60 m L/min: no adjustment; Clcr 30-59 m L/min: reduce dose to 39 mg/m^2; Clcr < 30 m L/min: not recommended (no data).
No specific Child-Pugh based modifications established; use caution in severe hepatic impairment; baseline dose reduction to 200-250 mg/m2 recommended in patients with bilirubin >1.5 mg/d L or transaminases >2x upper limit of normal.
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 25% (monitor toxicity); Child-Pugh C: not recommended (no data).
300-600 mg/m2 IV every 3-4 weeks; alternatively, 90-150 mg/m2 IV weekly for 4 weeks then 2-week rest. Adjust for renal function using Calvert formula with pediatric GFR estimation.
52 mg/m^2 intravenously over 2 hours daily for 5 days every 28 days (same as adult dosing per body surface area; safety and efficacy established in pediatric patients 1 year and older).
No specific dose adjustment solely for age; calculate dose based on GFR using Calvert formula; monitor for increased myelosuppression and neurotoxicity; consider starting at lower AUC (4-5) in patients with decreased renal function.
No specific dose adjustment based solely on age; monitor renal function closely due to increased risk of nephrotoxicity; use same dosing as adults with renal adjustment as per GFR.
Carboplatin should be administered under the supervision of a physician experienced in cancer chemotherapy. Myelosuppression is dose-dependent and may be severe, with bone marrow suppression requiring close monitoring. Anaphylactic reactions have been reported and may be fatal. Use caution in patients with prior hypersensitivity to platinum compounds.
Clofarabine causes severe bone marrow suppression, including neutropenia, anemia, thrombocytopenia, and increased risk of infection. Hemorrhage and severe infections have been reported. Monitor blood counts regularly.
Bone marrow suppression (thrombocytopenia, neutropenia, anemia) is dose-limiting; monitor blood counts. Nephrotoxicity may occur, especially in patients with renal impairment; assess renal function before and during therapy. Neurotoxicity (peripheral neuropathy) is less common than with cisplatin but may occur. Ototoxicity risk increases with higher cumulative doses. Anaphylactic reactions can occur. Hemolytic uremic syndrome has been reported. Use caution in patients with prior platinum hypersensitivity.
1) Myelosuppression: monitor CBCs; dose adjustment may be needed. 2) Infections: increased susceptibility. 3) Hemorrhagic cystitis: may occur; manage with hydration and monitoring. 4) Hepatic toxicity: monitor liver function tests; dose reduction in hepatic impairment. 5) Renal toxicity: monitor renal function; dose adjustment for creatinine clearance <60 m L/min. 6) Tumor lysis syndrome: hydrate and use prophylactic allopurinol. 7) Systemic inflammatory response syndrome (SIRS): monitor for signs; discontinue if occurs.
History of severe allergic reactions to carboplatin or other platinum-containing compounds; severe bone marrow suppression; significant bleeding disorders; severe renal impairment (creatinine clearance < 30 m L/min) unless benefit outweighs risk.
Hypersensitivity to clofarabine or any component of the formulation; severe hepatic impairment (Child-Pugh class C); severe renal impairment (creatinine clearance <30 m L/min).
No significant food interactions. Avoid grapefruit and grapefruit juice if patient is on concurrent CYP3A4-metabolized drugs (e.g., aprepitant).
Grapefruit and grapefruit juice may affect liver enzymes and should be avoided. No specific food restrictions, but avoid alcohol due to potential hepatotoxicity. Maintain adequate hydration; no other known food interactions.
Pregnancy Category D. First trimester: High risk of teratogenicity; embryotoxicity, fetal malformations (neural tube, skeletal, cardiovascular). Second and third trimesters: Risk of fetal growth restriction, prematurity, low birth weight, neonatal myelosuppression, and long-term developmental effects.
Clofarabine is embryotoxic and teratogenic in animal studies. In humans, it is classified as Pregnancy Category D. First trimester exposure is associated with major congenital malformations including neural tube defects, skeletal anomalies, and cardiovascular defects. Second and third trimester exposure may cause fetal myelosuppression, intrauterine growth restriction, and premature delivery.
Excreted in human milk; no M/P ratio available. Risk of severe neonatal adverse effects; contraindicated during breastfeeding. Discontinue drug or nursing.
It is unknown whether clofarabine is excreted in human breast milk. Due to the potential for serious adverse reactions in nursing infants, breastfeeding is contraindicated during therapy and for at least 1 week after the last dose. M/P ratio is not available.
No established specific dose adjustments in pregnancy; physiological changes (increased plasma volume, enhanced renal clearance) may reduce systemic exposure; however, safety data insufficient. Use Calvert formula based on renal function; monitor for toxicity and adjust as needed.
No specific pharmacokinetic studies have been conducted in pregnant women. Dose adjustments based on pregnancy-induced physiologic changes (increased plasma volume, renal clearance) are not established. Use with caution; the lowest effective dose based on tolerability and clinical response is recommended. Close monitoring for toxicity is essential.
Paraplatin (carboplatin) dosing is based on renal function using Calvert formula to calculate AUC. Dose adjustments required for Cr Cl <60 m L/min. Administer IV infusion over 15-60 minutes. Hypersensitivity reactions may occur after multiple cycles; premedicate with antihistamines and corticosteroids if prior reaction. Monitor CBC weekly during treatment. Emetogenic potential: moderate-high; use antiemetic prophylaxis. Avoid concurrent nephrotoxic drugs. Myelosuppression (especially thrombocytopenia) is dose-limiting.
Clofarabine is a purine nucleoside antimetabolite used primarily in pediatric relapsed or refractory acute lymphoblastic leukemia (ALL). It is associated with significant myelosuppression; monitor absolute neutrophil count and platelets closely. Capillary leak syndrome and systemic inflammatory response syndrome (SIRS) are rare but serious adverse effects; consider prophylactic corticosteroids. Hepatic veno-occlusive disease (VOD) has been reported, especially in patients with prior stem cell transplant. Administer with adequate hydration and monitor for tumor lysis syndrome.
This drug may lower your blood cell counts; report any signs of infection (fever, chills), easy bruising or bleeding, or unusual tiredness.,You may experience nausea or vomiting; take anti-nausea medications as prescribed.,Avoid live vaccines during treatment and for 6 months after.,Tell your doctor if you have had an allergic reaction to platinum-based drugs.,Use effective contraception during and for 6 months after treatment; do not breastfeed.,Drink plenty of fluids to stay hydrated unless otherwise instructed.,Report any hearing changes, ringing in ears, or numbness/tingling in hands or feet.
Clofarabine is a chemotherapy drug that may lower your blood cell counts, increasing risk of infection, bleeding, and fatigue.,Report any signs of infection (fever, chills, sore throat), unusual bleeding or bruising, or shortness of breath immediately.,Drink plenty of fluids (8-10 glasses per day) to prevent kidney problems and tumor lysis syndrome.,Avoid live vaccines and close contact with people who have recently received oral polio vaccine.,Use effective contraception during treatment and for at least 6 months after the last dose.,Do not breastfeed while taking clofarabine.,You may experience nausea, vomiting, or diarrhea; your doctor can prescribe medications to manage these symptoms.
No interactions on record
"Clofarabine, a purine nucleoside antimetabolite used in hematologic malignancies, may reduce the metabolism of Eltrombopag, a thrombopoietin receptor agonist, via inhibition of UDP-glucuronosyltransferase (UGT) enzymes, particularly UGT1A1 and UGT1A3. This leads to increased systemic exposure of Eltrombopag, potentially elevating the risk of hepatotoxicity (e.g., elevated liver enzymes) and other adverse effects such as thrombosis. Clinical outcomes may include exacerbated liver injury, which is particularly concerning in patients with pre-existing hepatic impairment or those receiving other hepatotoxic agents."
"Concurrent use of clofarabine and mecamylamine may synergistically increase the risk of severe hypotension and syncope. Clofarabine is a purine nucleoside analog that can cause capillary leak syndrome and hypotension, while mecamylamine is a ganglionic blocker that inhibits sympathetic outflow, leading to orthostatic hypotension. The combined hypotensive effects may result in profound blood pressure reduction, dizziness, and potential falls, particularly in patients with impaired cardiovascular function."
"The combination of clofarabine and nifedipine may increase the risk of cardiotoxicity, particularly QT interval prolongation and left ventricular dysfunction. Clofarabine has been associated with pericardial effusion and cardiac tamponade, while nifedipine, a calcium channel blocker, can cause hypotension and reflex tachycardia, potentially compounding hemodynamic stress in patients with compromised cardiac function. Clinical outcomes may include arrhythmias, heart failure exacerbation, or sudden cardiac death, especially in patients with preexisting cardiovascular risk factors."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about PARAPLATIN vs CLOFARABINE, answered by our medical review team.
PARAPLATIN is a Antineoplastic Agent that works by Carboplatin, a platinum-based alkylating agent, forms interstrand and intrastrand DNA cross-links by binding to DNA guanine bases, inhibiting DNA replication and transcription, leading to cell cycle arrest and apoptosis.. CLOFARABINE is a Antineoplastic Agent that works by Clofarabine is a purine nucleoside antimetabolite that inhibits DNA synthesis by reducing intracellular deoxynucleotide triphosphate pools via inhibition of ribonucleotide reductase, and by terminating DNA chain elongation through incorporation into DNA, leading to apoptosis.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between PARAPLATIN and CLOFARABINE depend on the specific clinical indication. These are both Antineoplastic Agent agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of PARAPLATIN is: 360 mg/m2 IV every 3 weeks or area under the curve (AUC) 4-6 mg/m L/min IV every 3-4 weeks using Calvert formula.. The standard adult dose of CLOFARABINE is: 52 mg/m^2 intravenously over 2 hours daily for 5 consecutive days, repeated every 28 days.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between PARAPLATIN and CLOFARABINE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. PARAPLATIN is classified as Category C. Pregnancy Category D. First trimester: High risk of teratogenicity; embryotoxicity, fetal malformations (neural tube, skeletal, cardiovascular). Second and third trimesters: Risk o. CLOFARABINE is classified as Category C. Clofarabine is embryotoxic and teratogenic in animal studies. In humans, it is classified as Pregnancy Category D. First trimester exposure is associated with major congenital malf. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.